سعر ليبوميديزين 300 مجم 30 كبسولة 2022

Lipomedizen 300 mg (Medizen, Egypt): fenofibrate 300 mg capsules, a fibrate lipid-lowering agent; pack of 30.

• Adults only, as adjunct to diet and other non-pharmacological measures: severe hypertriglyceridaemia with or without low HDL-C; mixed hyperlipidaemia when a statin is contraindicated or not tolerated; mixed hyperlipidaemia at high CV risk combined with a statin when TG and HDL-C are not adequately controlled.Population: AdultsANSM (Agence nationale de sécurité du médicament et des produits de santé), France

• Muscle effects (diffuse myalgia, tenderness, weakness) and exceptional rhabdomyolysis; uncommon moderate effects: dyspepsia-type digestive disorders, transaminase elevation, gallstone formation; rarely rash, pruritus, urticaria or photosensitivity; very rare interstitial pneumopathy.International label, equivalent formulation · ANSM (Agence nationale de sécurité du médicament et des produits de santé), France

• Hepatic insufficiency; renal insufficiency; hypersensitivity to fenofibrate or excipients; known phototoxic or photoallergic reactions with fenofibrate or structurally related substances, especially ketoprofen; children; lactose intolerance conditions (contains lactose).International label, equivalent formulation · ANSM (Agence nationale de sécurité du médicament et des produits de santé), France

• Muscle damage including exceptional rhabdomyolysis (more frequent with hypoalbuminaemia); stop if diffuse myalgia, muscle tenderness or CPK > 5 x normal; higher risk over 70 years, hereditary muscle disorders, renal impairment, hypothyroidism, high alcohol intake; monitor transaminases every 3 months for the first 12 months and stop if AST/ALT > 3 x ULN; pancreatitis reported; closer INR monitoring with oral anticoagulants.International label, equivalent formulation · ANSM (Agence nationale de sécurité du médicament et des produits de santé), France

• HMG-CoA reductase inhibitors and other fibratesCombination not advised: increased risk of serious muscle toxicity; if used, close monitoring.ANSM (Agence nationale de sécurité du médicament et des produits de santé), France
• Oral anticoagulantsIncreased anticoagulant effect and bleeding risk; more frequent INR monitoring; reduce anticoagulant dose by one-third during treatment and for 8 days after stopping.ANSM (Agence nationale de sécurité du médicament et des produits de santé), France
• CiclosporinRisk of increased ciclosporin nephrotoxicity; monitor renal function during and after the combination.ANSM (Agence nationale de sécurité du médicament et des produits de santé), France

• Animal studies not teratogenic and no malformative or fetotoxic effect seen clinically so far, but follow-up of exposed pregnancies is insufficient; no indication for fibrates in pregnancy except major hypertriglyceridaemia (> 10 g/L) insufficiently corrected by diet with maternal acute pancreatitis risk.International label, equivalent formulation · ANSM (Agence nationale de sécurité du médicament et des produits de santé), France
• No information on passage into breast milk; prescription is therefore discouraged.International label, equivalent formulation · ANSM (Agence nationale de sécurité du médicament et des produits de santé), France

• Fenofibrate: Prodrug hydrolysed to fenofibric acid, which activates PPAR-alpha, increasing lipolysis and elimination of triglyceride-rich particles and reducing apoprotein C-III.